388 related articles for article (PubMed ID: 11368545)
1. Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation.
Xue L; Wang HF; Wang Q; Szklarz GD; Domanski TL; Halpert JR; Correia MA
Chem Res Toxicol; 2001 May; 14(5):483-91. PubMed ID: 11368545
[TBL] [Abstract][Full Text] [Related]
2. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe.
Wang H; Dick R; Yin H; Licad-Coles E; Kroetz DL; Szklarz G; Harlow G; Halpert JR; Correia MA
Biochemistry; 1998 Sep; 37(36):12536-45. PubMed ID: 9730826
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities.
Gillam EM; Guo Z; Ueng YF; Yamazaki H; Cock I; Reilly PE; Hooper WD; Guengerich FP
Arch Biochem Biophys; 1995 Mar; 317(2):374-84. PubMed ID: 7893152
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
5. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.
Shou M; Martinet M; Korzekwa KR; Krausz KW; Gonzalez FJ; Gelboin HV
Pharmacogenetics; 1998 Oct; 8(5):391-401. PubMed ID: 9825831
[TBL] [Abstract][Full Text] [Related]
6. Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
Ueng YF; Kuwabara T; Chun YJ; Guengerich FP
Biochemistry; 1997 Jan; 36(2):370-81. PubMed ID: 9003190
[TBL] [Abstract][Full Text] [Related]
7. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes.
Ueng YF; Shimada T; Yamazaki H; Guengerich FP
Chem Res Toxicol; 1995 Mar; 8(2):218-25. PubMed ID: 7766804
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of aflatoxin B1 oxidation by gestodene action on human liver microsomes.
Kim BR; Oh HS; Kim DH
Biochem Mol Biol Int; 1997 Nov; 43(4):839-46. PubMed ID: 9385444
[TBL] [Abstract][Full Text] [Related]
9. Cloning, expression and functional characterization of cytochrome P450 3A37 from turkey liver with high aflatoxin B1 epoxidation activity.
Rawal S; Yip SS; Coulombe RA
Chem Res Toxicol; 2010 Aug; 23(8):1322-9. PubMed ID: 20707407
[TBL] [Abstract][Full Text] [Related]
10. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation.
Domanski TL; Liu J; Harlow GR; Halpert JR
Arch Biochem Biophys; 1998 Feb; 350(2):223-32. PubMed ID: 9473295
[TBL] [Abstract][Full Text] [Related]
11. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity.
Domanski TL; He YA; Harlow GR; Halpert JR
J Pharmacol Exp Ther; 2000 May; 293(2):585-91. PubMed ID: 10773032
[TBL] [Abstract][Full Text] [Related]
12. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation.
Khan KK; He YQ; Domanski TL; Halpert JR
Mol Pharmacol; 2002 Mar; 61(3):495-506. PubMed ID: 11854429
[TBL] [Abstract][Full Text] [Related]
13. Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity.
Harlow GR; Halpert JR
J Biol Chem; 1997 Feb; 272(9):5396-402. PubMed ID: 9038138
[TBL] [Abstract][Full Text] [Related]
14. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics.
Harlow GR; Halpert JR
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6636-41. PubMed ID: 9618464
[TBL] [Abstract][Full Text] [Related]
15. Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis.
He YA; He YQ; Szklarz GD; Halpert JR
Biochemistry; 1997 Jul; 36(29):8831-9. PubMed ID: 9220969
[TBL] [Abstract][Full Text] [Related]
16. Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes.
Yamazaki H; Inui Y; Wrighton SA; Guengerich FP; Shimada T
Carcinogenesis; 1995 Sep; 16(9):2167-70. PubMed ID: 7554070
[TBL] [Abstract][Full Text] [Related]
17. Interaction of aflatoxin B1 with cytochrome P450 2A5 and its mutants: correlation with metabolic activation and toxicity.
Pelkonen P; Lang MA; Negishi M; Wild CP; Juvonen RO
Chem Res Toxicol; 1997 Jan; 10(1):85-90. PubMed ID: 9074807
[TBL] [Abstract][Full Text] [Related]
18. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity.
Domanski TL; He YA; Khan KK; Roussel F; Wang Q; Halpert JR
Biochemistry; 2001 Aug; 40(34):10150-60. PubMed ID: 11513592
[TBL] [Abstract][Full Text] [Related]
19. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4.
Roussel F; Khan KK; Halpert JR
Arch Biochem Biophys; 2000 Feb; 374(2):269-78. PubMed ID: 10666307
[TBL] [Abstract][Full Text] [Related]
20. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
